

# Novel Approaches to the Treatment of Hypothyroidism

NCT06731764

---

Status	RECRUITING
Phase	Phase 2, Phase 3
Sponsor	UConn Health
Enrollment	90 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- History of hypothyroidism Treatment with levothyroxine Levothyroxine dose  $\geq 1.2$  mcg/kg

### Exclusion (6)

- Body weight  $< 50$  or  $> 100$  Kg.
  - Indication for TSH suppression (high risk follicular-derived thyroid cancer).
  - Secondary (pituitary) hypothyroidism (ICD-10 E23.0); Pregnancy; breastfeeding; uncontrolled diabetes (HbA1c  $> 8.5\%$  at screening); use of oral Semaglutide (Rybelsus); Uncontrolled Hypertension (BP  $> 140/90$  at screening); current use of T3-containing therapies (Liothyronine, desiccated thyroid extracts).
  - Patients receiving lipid-lowering therapies must maintain the same dose throughout the participation in the study. Changes in lipid lowering therapy/dose will result in termination from the study.
  - Bariatric surgery, initiation of GLP-1 agonist therapy (irrespective of the indication), enrollment in structured weight loss programs will result in dismissal from the study.
- ... and 1 more (see full listing online)

## Locations (1 total)

---

UConn Health, Farmington, Connecticut, United States